William Shingler

Dr William Shingler leads Autolus’ Patient and Cell Management Team with a dual remit of Patient Scheduling and “Apheresis Operations”.  William has worked in cancer immunotherapy drug development for the past 20 years and immediately prior to joining Autolus led the technical onboarding of UK hospitals for Novartis’ Kymriah launch programme.  Previously he led the global clinical supply chain at Immunocore Limited (a T cell receptor-focused biotech), where he also held various clinical and drug development positions. Prior to this William was Principal Scientist in the clinical immunology group at Oxford BioMedica, focussed on their therapeutic cancer vaccine programme.  In June 2018, William obtained an MBA with distinction from the University of Oxford, Säid Business School, having previously gained his PhD studying apoptosis, cancer, and immunology at the University of Nottingham and the University of Edinburgh. He also holds a BSc in Biochemistry and Genetics from the University of Nottingham.